Ralph Minter

Dr. Minter is an expert in antibody discovery with over 20 years’ experience leading discovery teams and developing candidate drugs across multiple disease areas. Previously, he was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca. Prior to that he was part of Cambridge Antibody Technology (CAT), which later became MedImmune. In addition to antibody discovery, Dr. Minter is known for pioneering new technology platforms within the biologics field. An example of this is phenotypic, or target-agnostic, antibody screening which Dr. Minter instigated and ran for 15 years at CAT/MedImmune and which has yielded many novel therapeutic targets, some of which are now being tested in clinical trials.

Dr. Minter is an author on more than 35 papers, frequent invited speaker at antibody conferences and inventor on several patents. Dr. Minter holds a BSc in Pathology and Microbiology from Bristol University and a PhD in Immunology from Durham University.